Drugs / Candi5V
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06190509 | Dec 2023 → Apr 2027 expected | vulvovaginal candidiasis | LimmaTech Biologics AG | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Candi5V | “The candidate pentavalent bioconjugate vaccine (Candi5V) is administered twice, 2 months apart, with adjuvant.” NCT06190509 ↗ |
| Modality | Vaccine | “pentavalent bioconjugate vaccine” NCT06190509 ↗ |